This single-center retrospective analysis aims to evaluate the real-world outcomes of patients with moderate-to-severe AD treated with dupilumab and JAK inhibitors, with a specific focus on their short-term effect on serum galectin-7 levels, a potential biomarker reflecting IL-4/IL-13–induced skin barrier impairment [15], and one-year stability of effectiveness based on patient-oriented outcomes during the first year. This evidence concerns the gene IL13 and Alzheimer disease.